Leerink Partners, a leading healthcare investment bank, announced today
the addition of Daina Graybosch, Ph.D. to the firm’s Equity Research
team. Dr. Graybosch joins the firm as a Managing Director and Senior
Research Analyst within the Therapeutics team. In this role, Dr.
Graybosch will be leading the firm’s Immuno-oncology research efforts
and will be located in the firm’s New York office.
Dr. Graybosch joins Leerink Partners from McKinsey & Company where she
was most recently a Senior Expert and Head of McKinsey’s Center for
Asset Optimization, as well as the U.S. Head of the McKinsey Cancer
Center. In these roles, Dr. Graybosch developed several McKinsey
solutions that bring data and advanced analytics to pharmaceutical
development decisions. In her 11 years at McKinsey, Dr. Graybosch
developed a rich understanding of oncology through her work with
companies across the value chain, including Pharmaceutical, Diagnostic,
Academic Medical Center, and Genomic/Data. Dr. Graybosch earned a Ph.D.
in Chemistry and Chemical Biology from Harvard University and dual B.S.
degrees in Biology and Chemistry from the University of Utah.
John L. Sullivan, CFA, Senior Managing Director of Equity Research and
Healthcare Investment Strategist at Leerink Partners stated, “We welcome
Daina and her rich understanding of oncology drug development to Leerink
Partners. We are excited to have assembled a Therapeutics Research team
that will deliver market-leading analysis of the fundamentals and
opportunities in the biopharmaceutical industry.”
“Daina’s experience in therapeutics makes her a valuable addition to our
team,” stated Geoffrey Porges, MBBS, Director of Therapeutics at Leerink
Partners. “She brings unique expertise, having worked on many projects
in oncology and across different aspects of pharmaceutical discovery and
development. Daina’s technical and industry experience will complement
the skills of our other analysts and bring unique investable insights to
“I am excited to join Leerink Partners,” stated Dr. Graybosch. “With
unprecedented options for investment in oncology and beyond, Leerink
will be positioned to deliver research with unique depth backed by our
analysts’ experience and leading analytics.”
About Leerink Partners
Leerink Partners LLC is a leading investment bank, specializing in
healthcare. Our knowledge, experience and focus enable us to help our
clients define and achieve their strategic, capital markets and
investment objectives. We partner with companies that develop and
commercialize innovative products and services that are defining the
future of healthcare. Leerink Partners LLC is a member of FINRA/SIPC.
For more information, please visit: www.leerink.com.
© 2018 Leerink Partners LLC. All rights reserved. Member FINRA/SIPC. www.finra.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005306/en/